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Ciliary Neurotrophic Factor: 
Pharmacokinetics and Acute-Phase 
Response in Rat 
Falk Dittrich, Hans Thoenen, and Michael Sendtner 
Ciliary neurotrophic factor (CNTF) supports the survival of motoneurons in vitro and in vivo. Recombinant CNTF 
is an investigational drug for the treatment of amyotrophic lateral sclerosis. We determined the pharmacokinetics of 
radioiodinated CNTF after intravenous injection into rats. CNTF shows a biphasic clearance with an initial plasma 
half-life of 2.9 minutes and is removed from the circulation by the liver. No accumulation of radioactivity was 
detectable in nerve tissue or skeletal muscle after intravenous injection of 0.1 J.l.g and 0.5 J.l.g of CNTF. Radioactive 
degradation products accumulate in the skin. Liver cells express specific binding proteins for CNTF, and the incorpora-
tion and degradation of intravenously injected CNTF by the liver may occur after association of CNTF with the 
soluble CNTF receptor IX in the circulation. Probably as a consequence of its binding to hepatocytes, CNTF induces 
acute-phase responses in liver. The short half-life and the inflammatory side effect may limit the clinical usefulness of 
systematically administered CNTF in the treatment of human motoneuron disorders. 
Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and 
acute-phase response in rat. Ann NeuroI1994;35:151-163 
Ciliary neurotrophic factor (CNTF) has originally been 
identified as a potent survival factor for a variety of 
neuronal cell types in vitro [l}, in particular, spinal 
motoneurons of embryonic chick and rat [2-4}. CNTF 
prevents the degeneration of motoneurons in vivo dur-
ing embryonic development when applied onto the 
chorioallantoic membrane of developing chick [5}, and 
in lesion experiments when delivered to the proximal 
stump of a lesioned facial nerve of newborn rats [6}. 
Transgenic mice lacking functional CNTF gene 
expression develop normally until birth but develop 
progressive atrophic and degenerative changes in mo-
toneurons after the first postnatal weeks [7}. This sug-
gests that the physiological function of CNTF might 
be confined to the maintenance of neuronal function 
in the adult rather than in survival and early differentia-
tion of neuronal cells during development. The finding 
that systemically delivered CNTF is capable of pre-
venting the degeneration and functional loss of moto-
neurons in the homozygous progressive motor neu-
ronopathy (pmn) mouse mutant [8}, an a~lmal model 
for human spinal motoneuron disease, has raised hopes 
that this factor might be useful in the treatment of 
human degenerative disorders such as amyotrophic lat-
eral sclerosis (ALS) [9}' However, little is known so 
far about the pharmacokinetics and the side effects of 
CNTF after systemic injection, information that is a 
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prerequisite for potential clinical use of this compound 
in humans. 
Endogenous expression of CNTF is found in my-
elinating Schwann cells of peripheral nerves as well as 
in a subpopulation of astrocytes, in particular, in the 
optic nerve and the olfactory bulb of adult rats [lO}. 
CNTF does not share any sequence homology or simi-
larity in biochemical properties with the members of 
the nerve growth factor (NGF) gene family of neuro-
trophic factors [ll}. Predictions of the protein struc-
ture of CNTF have suggested that CNTF has a helical 
framework similar to leukemia inhibitory factor (LIF), 
oncostatin M, interleukin-6 (IL-6), and granulocyte col-
ony-stimulating factor (G-CSF) [12}. However, CNTF 
differs from these molecules in that it is a cytosolic 
molecule that does not possess a signal peptide for 
secretion through the conventional endoplasmic retic-
ulum-golgi apparatus pathway. Moreover, CNTF 
does not appear to be glycosylated and lacks cysteine 
bridges, indicating that the physicochemical properties 
Of CNTF could significantly differ from those of its 
structural relatives [11-16}. Therefore, pharmacoki-
netic data obtained in vivo for recombinant human (rh) 
factors like rhIL-6 [I7} and rhG-CSF [18} and for mu-
rine LIF [19} might not necessarily be pertinent to 
CNTF. 
The membrane-associated CNTF receptor complex 
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appears to be composed of at least three subunits, the 
CNTF receptor a (CNTFRa), the glycoprotein gp130, 
and the LIF receptor f3 (LIFRf3) (for reviews, see [20-
22}). The structure of CNTFRa has been found to 
be unrelated to the receptors for NGF and related 
neurotrophins (23} but homologous to the low-affinity 
IL-6 receptor a (IL-6Ra) [20-22, 24}. The expression 
of CNTFRa has been described to be mainly restricted 
to the nervous system and skeletal muscle [24, 25}. It 
was concluded from these findings that actions of 
CNTF after systemic administration might be re-
stricted to these tissues. In this study we have exam-
ined the pharmacokinetics and some side effects of 
systemically administered CNTF in the rat. 
Materials and Methods 
Animals 
Adult male Wistar rats weighing 150 to 200 gm were used for 
all experiments. The rats were obtained from the breeding 
facilities of the Max-Planck-Institute of Biochemistry, where 
they are kept under specific pathogen-free conditions. Rats 
were supplied with food and tap water ad libitum throughout 
the course of the experiments. Experiments were performed 
in accordance with Bavarian state legislation. 
Radioiodination of C-terminal-modified CNTF 
Recombinant rat CNTF contains only four tyrosine residues 
[11} and could not be iodinated to high specific radioactivity 
without using large amounts of 1251-Na (P. Phelan, unpub-
lished results). Therefore, a modified recombinant rat CNTF 
with three additional C-terminal tyrosine residues, here de-
noted CNTFY, was designed by adding three codons for 
tyrosine to the 3' end of the coding region of the cDNA for 
rat CNTF (K. Stockli, unpublished results), expressed in 
E. coli as described [26] and used for iodination. Both CNTF 
and CNTFY were purified from transfected E. coli using a 
modification of the method described by Masiakowski and 
colleagues [26}, in which the chromatographic purification 
of the protein on DEAE-cellulose was replaced by a single 
reverse-phase, high-pressure liquid chromatography (HPLC) 
step on a preparative column (Vydac C4). Both CNTF and 
CNTFY eluted as a single peak at 50 to 55 % acetonitrile 
with 0.1 % trifluoroacetic acid, and migrated as a single band 
on a sodium dodecyl sulfate (SDS) containing polyacrylamide 
gel under reducing conditions (data not shown). The peak 
fractions, eluted from HPLC columns, were stored at - 70°C 
after addition of n-octyl-(3-o-glucopyranoside (final concen-
tration of 0.1 % ). Protein concentration was determined by 
amino acid analysis prior to use. 
Radioiodination was performed by addition of lactoperoxi-
dase (5.4 x 10 - 13 mol), H 20 2 (2.3 x 10-9 mol), and 0.3 
mCi of 125I_Na to 1 fLg of CNTFY (4.4 x 10- 11 mol) diluted 
in 50 fLl of 35 mM potassium acetate at pH 5. This mixture 
was incubated for 15 minutes at room temperature. After a 
further IS-minute incubation step with a second addition of 
H 20 2 (2.3 x 10-9 mol), the specific radioactivity of 1251_ 
CNTFY was determined by precipitating an aliquot of the 
reaction in 20% trichloroacetic acid (TCA) containing 0.25% 
bovine serum albumin (BSA) and 0.3% Nal, and measuring 
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Fig 1. Biological activity of ciliary neurotrophic facto I' ICj\"TF,. 
CNTFY (CNTF with three additional C-terminal tyrosine resi-
dues), and 125[_CNTFY. Survival of cultured embry'ollic do)' 8 
chick ciliary neurons in the presence of CNTF (e ). Ci\ -TFY 
CY), and 125[_CNTFY (_). Surviving neurons u"ere cOllllted 
24 hours after the addition of 10 pg. 50 pg, 100 pg, 500 pg, 
1 ng. or 5 ng of factor. Each point represents the meall of fl[,O 
determinations; bars represent the range. For imprOl"ed clon"'J 
the points for CNTFY and 125[_CNTFY are shifted to tbe left 
and right. respectively, 
the radioactivity of the precipitate. An average specific radio-
activity of 1.39 x 10R cpm/fLg was determined, which is 
equivalent to mean incorporation of 1.7 1251 per molecule of 
CNTFY. For further applications, free iodine was removed 
by size exclusion chromatography using Sephadex G-50. 
1251-CNTFY was eluted with Krebs-Ringer-HEPES buffer 
(KRH) at pH 7.3, giving a concentration of 1 to 1.5 fLg/ml. 
Bioassay 
The chick ciliary neuron survival assay was performed as de-
scribed [27}. Surviving neurons were counted after 24 hours 
in culture, and the factor concentration that supported half-
maximal survival of the cultured neurons was found to be 
50,62, and 70 pg/ml for CNTF, CNTFY, and 125I_CNTFY, 
respectively (Fig 1). Taking into account the variability of 
the assay, the biological activity of all three molecules was 
indistinguishable. 
Detection of Intravenously Injected 125I_CNTFY 
Clearance and tissue distribution of CNTF was determined 
after injection of 0.1 or 0.5 fLg of m I-CNTFY in 300 fLlof 
phosphate-buffered saline (PBS) into the tail vein of ether-
anesthetized adult male Wistar rats (150-200 gm). At differ-
ent time points after injection, the rats were killed by ether 
overdose and blood was obtained by heart puncture. Organs 
were removed after perfusion with 100 ml ofPBS containing 
1,000 units of heparin to remove vascular- from tissue-bound 
125I-CNTFY. We chose this technique because no vascular 
marker was available showing identical distribution in the 
circulation as CNTF. The weight of wet tissue of the pre-
pared organs was measured and the radioactivity was counted 
for 10 minutes in a gamma counter. Aliquots of the tissues 
were homogenized and precipitated in 20% TCA to deter-
mine the extent of degradation of 125I_CNTFY. 
Autoradiography of Polyacrylamide Gels 
Discontinuous polyacrylamide gel electrophoresis (PAGE) 
[28} was used for further analysis of blood and tissues col-
lected at different times after intravenous (i. v.) injection of 
125I_CNTFY. For SDS-P AGE under reducing conditions the 
separations were performed for serum on 4 to 15% gradient 
gels, for liver extracts on 10 to 20% gradient gels, and for 
liver cell membrane proteins cross-linked to 125I_CNTFY on 
6.5% gels. Serum was also separated by PAGE at pH 9.5 
under nondenaturating conditions on 4 to 15 % gradient gels 
prepared without SDS. The gels were dried and exposed to 
x-ray films (Fuji, RX) at - 70°C with intensifying screens. 
Band intensities were determined by scanning the autoradio-
grams with a densitometer (Molecular Dynamics). 
Autoradiography of Tissue Sections 
At various time periods after i.v. injection of 0.1 /-Lg 0.94 
X 107 cpm) of 125I-CNTFY, rats were perfused with 0.01% 
lidocaine in PBS and subsequently with 4% paraformalde-
hyde in PBS. Tissues were dissected, postfixed for 2 hours, 
dehydrated by several washing steps with 20% sucrose in 
PBS, and frozen sections (7 /-Lm) were prepared. Finally, 
these sections were dipped in LM-l emulsion (Amersham) 
and developed after at least 3 days according to manufactur-
er's directions. After washing, the slides were stained with 
hematoxylin and eosin. 
Cross-Linking of 125I_CNTFY In Situ 
Five minutes after i.v. injection of 0.5 /-Lg (7 .1 X 107 cpm) 
of 125I_CNTFY, rats were killed by ether overdose and 10 
ml of KRH containing the cross-linking agent 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) at a concentration 
of 300 mM was injected into the liver via the portal vein. 
After 20 minutes of incubation on ice,S ml of 1 M glycine 
in PBS was injected via the portal vein to stop the reaction. 
The liver was removed and minced in homogenization buffer 
at pH 7.4 containing sucrose (0.25 mM), NaHC03 0 mM), 
MgCl2 (2 mM), glycine (1 M), phenylmethylsulfonyl fluoride 
o mM), aprotinin (l.5 /-LM), and leupeptin (2.4 /-LM) with 
a glass-glass homogenizer by 15 strokes at 500 rpm. Cell 
membranes were pelleted by centrifuging the homogenate 
(10 minutes, 1,000 g at 4°C). The pellet was washed once 
with homogenization buffer and the membranes were further 
purified by two-polymer phase partitioning as described [29}. 
The interphase was lysed in Tris-buffered saline at pH 7.4 
containing 1 % Nonidet P-40 and 10% glycerol, and insolu-
ble residues were removed by centrifugation for 5 minutes 
at 12,000 g. The supernatant was separated by SDS-PAGE 
and analyzed by autoradiography. 
Northern Blot Analysis of Acute-Phase Response 
Recombinant rat CNTF was lyophilized after dilution in a 
buffer suitable for i.v. injection in humans (Elomel, Boeh-
ringer) containing 0.25 % BSA (Sigma) with a low endotoxin 
content. When redissolved in pyrogen-free water, the CNTF 
showed no loss of biological activity (data not shown). CNTF 
was injected i.v. in a volume of 300 /-LI as described above, 
and after different time points the liver was removed from 
the killed rat and chilled in liquid nitrogen. RNA was ex-
tracted with guanidinium-thiocyanate and further purified by 
isopyknic gradient centrifugation in cesium trifluoroacetate 
[30}. Fifteen micrograms of total RNA were electrophoresed 
through l.2 % agarose gels containing formaldehyde (2 M) 
and vacuum-blotted to nylon membranes (Hybond-N, Amers-
ham). Hybridization was performed overnight at 42°C as 
described [1O} with 5 X 106 cpm/ml of a radioactive random 
prime-labeled cDNA probe for human haptoglobin [31]. 
Haptoglobin is induced as an acute-phase protein both in 
human and rat [32}. Rat haptoglobin shows 75% and 82% 
amino acid sequence identity with the (X- and f3-subunits of 
the human haptoglobin allele one gene product (33}; at the 
cDNA level, the sequence identity for the f3-subunit is ap-
proximately 78% [34}. After washing twO times in 2 X sa-
line-sodium citrate (SSC) containing 0.1 % SDS at room 
temperature and once for 30 minutes in 0.1 X SSC con-
taining 0.5 % SDS at 50°C, the blots were exposed to x-ray 
films (Fuji, RX) at - 70°C with intensifying screens. Band 
intensities were determined by scanning the auto radiograms 
with a densitometer (Molecular Dynamics). 
Results 
Clearance from the Blood of Intravenously 
Injected 125I_CNTFY 
Following i.v. injection of 0.1 f..Lg (1 x 107 cpm) of 
l2'iI-CNTFY, approximately 75% of the radioactivity 
was removed from the circulation within 10 minutes. 
The initial half-time of clearance (to .5) of 125I-CNTFY 
from the blood was 2.9 minutes, while the subsequent 
decrease of 125I-CNTFY levels in the blood was less 
rapid (to .5' 4 hr) (Fig 2). The highest tissue concentra-
tions of 125I_CNTFY 10 minutes after i.v. injection 
were found in the liver (6.88 ± 0.23 x 105 cpm/gm 
of tissue) (Fig 3a), indicating that about 70% of the 
injected radioactiviry has accumulated in this organ (to-
tal wet weight of liver, 11 .5 gm). At the same time, 
the levels of radioactivity in the urine were still very 
low, and the kidneys contained only about 7% of the 
injected radioactivity (3.86 ± 0.4 x 105 cpm/ gm of 
wet tissue), confirming that the rapid removal of 1251_ 
CNTFY from the circulation within the first 10 min-
utes occurred via the liver rather than by renal clear-
ance. At 6 hours after i.v. injection, more than 70% 
of the total amount of injected radioactivity was detect-
able in the skin. Thus, removal of 125I-CNTFY and 
its radioactive degradation products by renal clearance 
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Fig 2. Clearance of intravenously injected 1251-CNTFY from 
rat blood. At different time points (2.5 min to 16 hr) after in-
jection of 0.1 f.Lg (J X 107 cpm) of 1251_CNTFY into the tail 
vein of male Wistar rats (J 50-200 gm) , blood was collected by 
heart puncture and radioactim·ty was measured. Each point rep-
resents the mean of determinations from 3 or 4 ratJ. The insert 
shows the same data from 2.5 minutes to 30 minutes after injec-
tion only. Error bars represent the standard deviation (SD). 
Two elimination phases with plasma half-lives for 1251_ 
CNTFY of 2.9 minutes and 4 hours. respectively. were ob-
tained by best curz:e fitting using the GraFit program. 
seems to play only a minor role in removing the radio-
activity from the circulation also during the second 
slower clearance phase. Indeed, levels of measurable 
radioactivity in the urine were quite low (0.4 x 105 
cpm/ 50 f.LI at 10 minutes, 1.7 x 105 cpm/ 50 f.LI at 60 
minutes, and 0.3 x 105 cpm/50 f.L1 at 3 hours after i.v. 
injection), suggesting that less than 10% of the in-
jected radioactivity is removed by renal clearance 
within 3 hours after i.v. injection of 125I_CNTFY. 
Binding Proteins for 125I_CNTFY in the Blood 
The autoradiograms of serum samples collected within 
1 hour after i.v. injection of 0.1 f.Lg (l X 107 cpm) of 
125I-CNTFY and separated by SDS-PAGE showed a 
predominant 125I_CNTFY band and two much fainter 
bands at 45 kd and 14 kd, respectively (Fig 4a, lane 
S). During the first hour after i.v. injection the intensity 
of all three bands decreased, but no further radioactive 
band appeared that might result from potential degra-
dation fragments of 125I_CNTFY (see Fig 4a). By run-
ning the same serum samples on a nondenaturating 
polyacrylamide gel, it became apparent that after i.v. 
injection 125I_CNTFY is associated with two plasma 
proteins (Fig 4b). Most of the i.v. injected 125I-CNTFY 
was bound to the smaller plasma protein. 125I-CNTFY 
bound to this protein could be detected by autoradiog-
raphy at a relative migration position corresponding 
to the 94-kd protein phosphorylase b. 125I-CNTFY 
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Fig 3. Tissue distribution of radioactit'ity after intravenous in-
jection of 1251-CNTFY (1 25I-labeled ciliary neurotrophic factor 
with three additional C-terminal tyrosine residues) in rat. At 
different time points after injection of 125I_CNTFY into the 
taill!ein of male Wistar rats (150-200 gm). the specific radio-
actil!ity in different organs was measured (AJ 10 minutes to 
6 hours after injection of 0.1 f.Lg (1.13 x 107 cpml and 
(8) 12 hours after injection of 0.5 f.Lg (7.2 x 107 cpml of 
1251-CNTFY. Data represent the mean of determinations from 
3,104 rats and error bars represent the SD. 
c.v Cl) 1 2 S -\, 01 0 0 3 3 3 3 
-. Fig 4. Fate of 1251_CNTFY (1251-labeled ciliary neurotrophic 
::l ::l ::l :::::J factor ( 1251-CNTFJ with three additional C-terminal tyrosine 
residues) in rat blood after intratlenous injection. Serum ob-
tained at indicated time points after injection of 0 .1 }.tg (1 X 
]07 cpm) of 1251_CNTFY into the tail vein of male Wlstar rats 
(150-200 gm) was separated on polyacrylamide gefJ and ana-
lyzed by autoradiography. The arrow marks the 1251_CNTFY 
band. (a) Sodium dodecyl sul/ate-polyacrylamide gel electrophore-
sis (SDS-PAGE) under reducing conditiom 0/60-pl serum ali-
quots using a 10 to 20% gradient gel; S = aliquot of 1251_ 
CNTFY solution (300 pg, 3 X 104 cpm) prior to injection; 
the 45-kd and the 14-kd band are dimers and degradation prod-
ucts oj I251-CNTFY respectively. as determined by western blot 
analysis with different CNTF-peptide antisera (data not 
shown); exposure time = 2 days. (b) PAGE under nondenatur-
ating conditiom of 20-pl serum aliquots using a 4 to 15% gra-
dient gel. (c) PAGE under nondenaturating conditiom using a 
4 to 15 % gradient gel; prior to electrophoresis . 10 }.tg of cyto-
chrome c was loaded in all lanes to increase the protein concen-
tration; boxline serum albumin (BSA,' 67 kdJ and phosphorylase 
b (P: 94 kd) were run on the same gel and their indicated loca-
tion was determined by staining with Coomassie Blue; S = ali-
quat oj I25 I-CNTFY solution (260 pg. 2.6 x 104 cpm) prior 
to injection; lane I = 20-pl serum aliquot obtained 5 minutes 
after intraz1enous injection of 125I_CNTFY; lane 2 = 2.5 }.tg 
oj human armacroglobulin (S igma M -715 I) was incubated jor 
I hour at 37°C with I ng of 1251_CNTFY in ]0 pl of 
::s J ::s 20 mM sodium phosphate buffer at pH 7.4. and an allquot of 2 X 104 cpm was used for electrophoresis . 
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associated with the larger plasma protein migrates to 
the same position as 125I-CNTFY bound to human ar 
macroglobulin (a2M) (Fig 4c). 
Tissue Distribution of 125I_CNTFY after 
Intravenous Injection 
During the first hour after i.v. injection of 0.1 fLg or 0.5 
fLg of 125I_CNTFY, the highest tissue concentrations of 
125I_CNTFY were detected in the liver. The levels of 
specific radioactivity in the liver declined during the 
following 6 hours to a similar low level as in the blood. 
During this time period, the levels of specific radioac-
tivity in the skin increased gradually to levels that were 
higher than those in the liver (see Fig 3a). Unexpect-
. edly, spinal cord, brain, and skeletal muscle, tissues 
that are all known to express relatively high amounts 
of the CNTFRa mRNA [24, 25], did not show any 
accumulation of radioactivity within 6 hours after i.v. 
injection of 125I_CNTFY (see Fig 3a). Twelve hours 
after i.v. injection, levels of radioactivity in 10 mg of 
desanguinated skeletal muscle were less than 15% of 
those detectable in 10 fLl of blood. In the nervous 
system, relatively high levels of specific radioactivity 
were found only in the superior cervical ganglion 
(SCG) (500 cpm/lO mg of tissue) and sciatic nerve 
(200 cpm/IO mg of tissue), while the dorsal root gan-
glia contained less than 130 cpm/lO mg of tissue. Au-
tOradiograms of spinal cord and brainstem did not 
show any accumulation of radioactivity (data not 
shown). Indeed, the levels of specific radioactivity in 
these tissues were less than 40 cpmllO mg (see Fig 
3b), corresponding to maximally 0.28 pg of intact 1251_ 
CNTFY per 10 mg of tissue, which is equivalent to 
not more than one trophic unit per gram of tissue. 
Degradation of 125I_CNTFY by Liver Cells 
To study the fate of 125I-CNTFY in the liver after i.v. 
injection, we separated liver homogenates by SDS-
PAGE. Two major bands were detectable by autoradi-
ography, an upper band, corresponding to 1251_ 
CNTFY, and a lower band at 14 kd, which is about 
10 times less intensive and already detectable in the 
1251-CNTFY preparation after radioiodination (Fig 5). 
Between 1 and 3 hours after i.v. injection the intensity 
of the 1251-CNTFY band declined significantly (more 
Fig 5. Degradation 0/ intravenously injected 125I_CNTFY 
e25I-labeled ciliary neurotrophic factor with three additional C-
terminal tyrosine residues) in rat liver. Liver was excised at dif 
/erent time points after injection 0/0.1 p..g 0.77 X 107 cpm) 
0/125I_CNTFY into the tail vein 0/ male Wistar rats (J 50-
200 gm), homogenized, and the homogenate separated by sodium 
dodecyl su/fate-polyacrylamide gel electrophoresis on a 10 to 
20% gradient gel under reducing conditions and analyzed by 
autoradiography (exposure time = 2 weeks) . Size 0/ molecular 
mass markers is indicated in kilodaltons; the arrow marks the 
125I_CNTFY band; S = aliquot 0/ 125I_CNTFY solution (34 
pg, 6 X 103 cpm) prior to injection; the less intense 45-kd and 
the 14-kd bands in lane S are discussed in Figure 4. 
than 80 x), whereas the total radioactivity in the liver 
was reduced only 1.7 x. Simultaneously, a band at 7 
kd (presumably representing a proteolytic fragment of 
1251-CNTFY) increased in intensity. At 6 hours after 
injection, most of the 125I_CNTFY appeared to be de-
graded, and the presumptive 7 -kd proteolytic fragment 
represented the dominant band. Consistent with this 
observation, only 21 % of the radioactivity in liver, 
taken 6 hours after i.v. injection of 125I_CNTFY and 
subsequently homogenized, could be precipitated in 
20% TCA. Prior to injection, it was possible to precip-
itate 95% of the radioactivity from the 125I_CNTFY 
solution (Table). We could not analyze skin homoge-
nates by SDS-PAGE because their level of radioactiv-
ity was tOo low. However, 6 hours after i.v. injection 
of 125I_CNTFY, only 9% of the total radioactivity in 
skin could be precipitated (see Table). These data indi-
~ate that the accumulated radioactivity in skin (see Fig 
Trichloroacetic Acid-precipitable Radioactivity in Dif/erent Tissues 6 Hours after Injection 0/0.1 p..g 0.13 X 107 cpm) 0/ 
125I-CNTFY into the Tail Vein 0/ Male Wistar Rats 050-200 gm) 
Radioactivity TCA-precipitable Non-TCA-precipitable 
([cpm X 1O - 5}/gm wet tissue) (%) (%) 
125I-CNTFY 
solution 95 5 
Adrenal gland 0.14 74 26 
Liver 0.78 21 79 
Hairy skin 1.95 9 91 
125I-CNTFY = 125I-labeled ciliary neurotrophic factor with three additional C-terminal tyrosine residues. 
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3a) can be attributed primarily to breakdown products 
of 125I-CNTFY. In contrast, in adrenal gland 74% of 
the tissue bound radioactivity could be precipitated by 
TCA 6 hours after i.v. injection of 125I-CNTFY (see 
Table), suggesting that a major proportion of the radio-
activity measured represents intact 125I_CNTFY. 
Binding Sites oj125I-CNTFY on Liver Cells 
Autoradiograms of liver sections 1 hour after i.v. injec-
tion of 0.1 f.Lg 0.94 X 107 cpm) of 125I_CNTFY, when 
most of the factOr was not expected to be degraded 
(see Fig 5), showed an accumulation of silver grains 
over the cytoplasm and its compartments but not over 
the nuclei of rat liver cells (Fig 6). This indicates that 
a significant proportion of the i.v. injected 125I_CNTFY 
is taken up into the hepatocytes. 
To analyze whether the accumulation of i.v. injected 
125I_CNTFY in liver cells results from the interaction 
with specific CNTF binding sites, we performed cross-
linking studies to liver cells in situ with 125I_CNTFY 
(Fig 7). To do this we injected 0.5 f.Lg (7 .1 x 107 cpm) 
of 125I_CNTFY into the tail vein and 5 minutes later, 
the cross-linking agent EDC into the portal vein of 
male Wistar rats 050-200 gm). At that time a high 
amount of 125I-CNTFY has already accumulated in the 
liver and, if bound to membrane proteins, would be 
expected to be cross-linked to them under the condi-
tions used. Following cross-linking, SDS-PAGE of pu-
rified liver cell membrane proteins gave three bands 
of cross-linked proteins detectable by autoradiography 
at 99, 140, and 235 kd. 
Biological Effects 0/ CNTF in the Liver after 
Intravenous Injection 
Recently, it has been shown that recombinant rat 
CNTF increases mRNA levels of acute-phase proteins 
in hepatOcytes in vitro (31, 35}. The accumulation of 
125I-CNTFY in liver after i.v. injection (see Fig 3a) 
raises the question as to whether CNTF also induces 
acute-phase responses in vivo. To investigate this, the 
level of haptoglobin mRNA in the liver was deter-
mined by northern blot analysis after i.v. injection of 
CNTF (Fig 8). Time course analysis showed that the 
level of haptOglobin mRN A in the liver reaches a maxi-
mum 8 hours after i.v. injection of 10 f.Lg of CNTF 
(Fig 8a). The level of haptOglobin mRNA in CNTF-
treated rats at this time was significantly greater by a 
factor of 2.3 (Student's t test, p = 0.005; n = 5) than 
in control rats injected with the same volume of buffer 
(Fig 8c). Also 6 hours after i.v. injection of 10 f.Lg of 
CNTF, a more than 2 x higher haptoglobin mRNA 
level was detectable in comparison with control rats 
(Fig 8b). Furthermore, the increase of haptOglobin 
mRNA level 6 hours after i.v. injection of CNTF was 
dose dependent (Fig 8d). These results indicate that 
the effects of CNTF on hepatocytes are not confined 
Fig 6. Distribution of 125I_CNTFY (125I-Iabeled ciliary neuro-
trophic factor with three additional C-terminal tyrosine resi-
dues) in rat liver cells after intravenous injection. One hour 
after injection of 0.1 f.Lg (1 .94 x 107 cpm) of 125I_CNTFY 
into the tail tJein of male Wistar rats (150-200 gm), the liver 
was perfused in situ with phosphate-buffered saline (PBS) and 
subsequently with 4% paraformaldehyde in PBS. After postfix-
ation and dehydration 7 -f.Lm frozen sections were prepared and 
analyzed by autoradiography as described in Materials and 
Methods. Bright-field (a) and dark-field (b) photomicrographs re-
vealed the accumulation of silver grains over the cytoplasm and 
its compartments but not over the nuclei of rat liver cells. 
(x 400 before 22% reduction.) 
to cultured cells but also occur in vivo after pharmaco-
logical administration of CNTF. 
Discussion 
To be of therapeutic value in the treatment of degener-
ative motOneuron disease, CNTF should be accessible 
to motOneurons, for example via their endplates, 
where proteins are taken up from the circulation (36}. 
Therefore, we studied the pharmacokinetics of CNTF 
after i.v. injection. For our experiments we used iodin-
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Fig 7. Cross-linking 0/ 1251_CNTFY (i 251-labeled ciliary neuro-
trophic factor with three additional C-terminal tyrosine resi-
dues) to membrane proteins 0/ rat liver cells in situ. Five min-
utes after injection 0/0.5 J-Lg (7.1 X 107 cpm) 0/ 12lI-CNTFY 
into the tail vein 0/ a male Wistar rat (200 gm) la mlo/ 
Krebs-Ringer-HEPES buffer containing the cross-linking agent 
l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (300 mM) was 
injected into its portal vein. Membrane proteins were purified 
from liver, separated by sodium dodecyl sul/ate-polyacrylamide 
gel electrophoresis under reducing conditions on a 6.5 % gel, and 
finally analyzed by autoradiography. Size 0/ molecular mass 
markers is indicated in kilodaltons. 
ated, C-terminally modified recombinant rat CNTF 
e25I-CNTFY), whose biological activity in the chick 
ciliary neuron assay was indistinguishable from unmod-
ified CNTF (see Fig 1). Intravenously injected 1251_ 
CNTFY shows biphasic clearance kinetics with a fast 
initial phase (see Fig 2) similar to the kinetics of rhIL-6 
after i.v. injection into rats [I7}, of rhG-CSF injected 
i.v. into humans [37} and of murine recombinant LIF 
i.v. injected into mice [I9}. We could not decide from 
our results whether the rwo deduced elimination 
phases of 125I_CNTFY would best be described as a-
and [3-phases or [3- and 'Y-phases of drug elimination. 
For experimental reasons blood sampling by heart 
puncture was not possible earlier than 2.5 minutes 
after i.v. injection into the tail vein. Thus, if the first 
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elimination phase of 125I_CNTFY occurred before this 
time, it would not be detected in our experiments. 
Corresponding experiments with unlabeled recom-
binant rat CNTF detected in serum by a rwo-site en-
zyme-linked immunosorbent assay [38} have shown 
similar results. Also in this experimental paradigm, the 
initial plasma half-life of CNTF was shorter than 10 
minutes, suggesting that the rapid disappearance of ra-
dioactivity from the blood is not due to cleavage of the 
C-terminal 125I-tyrosine residues from the 125I-CNTFY 
molecule or to deiodination. 
Analysis of the tissue distribution of 125I-CNTFY 
after i.v. injection revealed a correlation berween the 
fast elimination from the blood (see Fig 2) and the 
accumulation of 125I-CNTFY in the liver (see Fig 3a). 
This situation is similar to that observed for the struc-
turally related compound IL-6. Most of this factor 
(80%) is taken up by the liver 20 minutes after i.v. 
injection into rats [I7}. In contrast, for LIF, another 
structural analogue of CNTF, the fast elimination after 
i.v. injection into mice has been shown to be due to 
clearance by the kidneys [I9}. Our data suggest that 
bolus i.v. injection might be inadequate for clinical 
CNTF administration because it leads to poor bioavail-
ability of CNTF for motoneurons. Moreover, these 
results might also have implications for subcutaneous 
injection of CNTF. Although long-term serum levels 
of proteins after subcutaneous injection might be 
higher than those after i.v. injection, as was shown for 
rhG-CSF [I8}, a significant proportion of subcutane-
ously injected CNTF would pass the liver once it has 
entered the bloodstream. Thus, other manners of 
CNTF application should be considered (see below). 
That the elimination of i.v. injected 1251_CNTFY by 
the kidneys apparently does not play a major role in 
the clearance of this factor suggests that 125I_CNTFY 
might bind to plasma proteins. PAGE analysis under 
nondenaturating conditions shows the binding of 1251_ 
CNTFY to rwo distinct plasma proteins (see Fig 4b). 
The smaller plasma protein seems to have a molecular 
mass of less than 100 kd. 
Recently, soluble CNTFRa (sCNTFRa), which has 
a molecular mass of 68 kd, has been detected in human 
cerebrospinal fluid and blood plasma [39}' Thus, it is 
tempting to speculate that the smaller plasma protein 
shown in Figure 3b, binding most of the 125I_CNTFY, 
could be sCNTFRa. SDS-PAGE analysis under reduc~ 
ing conditions of the same blood samples revealed ei-
ther that 125I_CNTFY is not degraded after i.v. injec-
tion in the blood, at least not during the first hour after 
injection (see Fig 4a), or that its fragments are removed 
from the circulation immediately after degradation. In 
contrast, a radiolabeled 7 -kd polypeptide was detect-
able in liver extracts, which progressively increased in 
relative intensity compared with the 125I-CNTFY band 
during the first 6 hours, during which time the intensity 
\ 
l 
\I 
{ 
Fig 8. Stimulation of haptoglobin gene expression in rat liver by 
ciliary neurotrophic factor (CNTF). Recombinant rat CNTF 
was diluted in buffer (see Materials and Methods), lyophilized, 
redissolved in pyrogen-free water, and injected into the tail vein 
of ether-anesthetized male Wistar rats (150-200 gm). At differ-
ent times after injection, total RNA was extracted from liver 
and subjected to northern blot analysis. The filters were hybrid-
ized with a radioactive random prime-labeled cDNA probe for 
human haptoglobin and the resultant autoradiograms scanned 
for densitometric analysis. Hp = haptoglobin mRNA. (a) Time 
course of haptoglobin mRNA level after injection of 10 J.Lg of 
. CNTF. (b) Six hours after injection of 10 J.Lg of CNTF (lane 
3) the level of haptoglobin mRNA was 3.1 X higher than in 
noninjected control rats (lane 1) and 2.2 X higher than in rats 
injected with the same volume of buffer only (lane 2); size of 
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RNA markers is indicated in kilobases; 28S rRNA and 18S 
rRNA were stained with methylene blue on the blot to demon-
strate that the same amounts of total RNA were loaded in each 
lane (lower panel). (c) Increase in haptoglobin mRNA level at 8 
hours after injection of 10 J.Lg of CNTF ( + CNTF) by a factor 
of 2.3 in comparison with control rats injected with the same 
volume of buffer only ( - CNTF); statistical significance tested 
by Student's t test: p = 0.005; n = 5 in each group. 
(d) Dose-response correlation between haptoglobin mRNA level 
and the amount of CNTF injected at 6 hours after injection. 
The basal haptoglobin mRNA level (set to 100%) was deter-
mined from rats injected with the same volume of buffer only . 
The bar represents the haptoglobin mRNA level in rats 24 
hours after intramuscular injection of 250 J.Li of turpentine. 
as a positive control. 
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of the 1251-CNTFY band decreased (see Fig 5). The 
7 -kd polypeptide may be a proteolytic fragment of 1251_ 
CNTFY. Many proteins, including IL-6 and NGF have 
been shown to be protected from proteolysis after 
binding to a 2M in the blood [40, 41J. Correspond-
ingly, the larger plasma protein, which binds 1251_ 
CNTFY (see Fig 4b), might be a 2M. In support of this 
hypothesis, we found that 1251_CNTFY, associated with 
the larger plasma protein, migrates to the same position 
as 1251-CNTFY bound to human a 2M (see Fig 4c). 
The accumulation of 1251_CNTFY in the liver after 
i.v. injection was surprising, as CNTFRa, the primary 
CNTF binding site on CNTF-responsive cells [42J, 
was not expected in high amounts in this organ ac-
cording to the reported levels of CNTFRa mRN A 
[24, 25]. However, high amounts of cell membrane-
associated CNTFRa might not be necessary for the 
accumulation of 125I_CNTFY in the liver, if one as-
sumes that most of the i.v. injected CNTF becomes 
associated with sCNTFRa in the blood. The 1251_ 
CNTFY I sCNTFRa complex might then bind in the 
liver to other subunits of the CNTF receptor complex 
associated with the cell membrane [39, 43J and present 
on liver cells (Fig 9 as a model of CNTF disposition 
after i.v. injection). Under these assumptions, the accu-
mulation of CNTF in liver would require that these 
other subunits are highly expressed in cells of this organ. 
The cell membrane-associated CNTF receptor com-
plex has been suggested to be composed of at least 
three subunits, CNTFRa, gp130, and LIFR[3 [20-22, 
39, 43, 44]. The glycoprotein gp130 has been shown 
to transduce the CNTF signal, most likely together 
with at least one other component, which might be the 
LIFR[3 [22, 39, 43, 44J, and to be highly expressed by 
liver cells [25}. Therefore, binding of a 125I_CNTFYI 
sCNTFRa complex to gp 130 might mediate the accu-
mulation of 1251-CNTFY in the liver. The model of the 
cell membrane-associated CNTF receptor complex is 
consistent with our results obtained by cross-linking of 
125I-CNTFY to liver in situ (Fig 7). Taking into account 
a molecular mass of 23 kd for 125I_CNTFY, we ob-
served a cross-linked protein of 76 kd on liver cells, 
which is the expected size of the rat CNTFRa [24, 39J. 
It has been proposed that on primary rat hepatocytes, 
CNTF binds to the IL-6Ra [35J, which has a molecular 
mass of approximately 80 kd [32]. However, CNTF 
does not bind to the soluble IL-6Ra, and a hepatoma 
cell line lacking the IL-6Ra responds to CNTF [31]. 
Therefore, it is highly likely that 125I_CNTFY is cross-
linked to rat liver cells (i.e., predominately hepato-
cytes) in situ to CNTFRa. Two other bands detectable 
after cross-linking of 125I-CNTFY to liver cells in situ 
showed relative molecular masses of about 140 kd and 
235 kd (see Fig 7). The molecular mass of gp130 ex-
pressed on a rat sympathoadrenal progenitor cell line 
has been reported to be 145 kd [25J, and for the ungly-
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Fig 9. Model of ciliary neurotrophic factor (CNTF) disposition 
after intravenous (i. v.) injection. After i.v. injection CNTF be-
comes associated with the soluble CNTF receptor a (sCNTFRa) 
in the circulation. On the celf membrane of liver celfs and other 
CNTF-responsive celfs in vivo. the CNTFlsCNTFRa complex 
associates with gp130 and LlFRf3 to form a functional CNTF 
receptor complex. 
cosylated human form of gp130, a molecular mass of 
lOl kd has been determined [45, 46]. Therefore, the 
cross-linked band of 140 kd could result from 1251_ 
CNTFY bound to gp130 being tissue-specifically gly-
cosylated to a lesser extent than in neuronal cells. The 
235-kd band could represent 12SI_CNTFY cross-linked 
to the LIFR[3, as the molecular mass of the glycosylated 
form of the human placental LIFRI3 is 190 kd [47]. 
Thus, on liver cells, the initial steps of signal transduc-
tion following CNTF binding may be identical to those 
described for neuronal cell lines [44J and for an eryth-
roleukemia cell line [43]. 
Six hours after i.v. injection of 125I-CNTFY, radioac-
tivity accumulated in the hairy skin, the tissue with the 
highest specific radioactivity at this time point (Fig 3a). 
This is strikingly similar to the tissue distribution of 
125I_rhIL_6 after i.v. injection in the rat: At 5 hours, the 
radioactivity attributable to 1251_rhIL_6 in liver had de-
clined significantly and high levels were found in skin, 
which radioactivity was suggested to be degradation 
products of 1251_rhIL_6 generated by fibroblasts [48]. 
In contrast, our results indicate that the degradation of 
1251_CNTFY has already taken place in the liver (see 
Fig 5), and that the radioactivity accumulated in the fat 
cells of the hairy skin (data not shown) does not repre-
sent intact 125I_CNTFY, but breakdown products (see 
Table). 
Our data suggest that 1251_CNTFY does not accumu-
late in skeletal muscle after systemic administration 
(see Fig 3a). Even 12 hours after injection, the specific 
radioactivity detectable in skeletal muscle was low~r 
than that of either liver, adrenal gland, or the SCG (see 
Fig 3b). This seems to be at odds with the reported 
high abundance of CNTFRa mRNA in skeletal muscle 
[24, 25]. Recently, it was suggested that, after nerve 
injury, a significant proportion of the CNTFRa pro-
duced in skeletal muscle is released into the circulation 
[39]. If this also happens in unlesioned animals, i.v. 
injected CNTF might bind to soluble and not cell 
membrane-associated CNTFRa in skeletal muscle. 
Preferential accumulation of 1251-CNTFY/sCNTFRa 
complex in the liver rather than in skeletal muscle may 
thus be due to a relatively high expression of gp 130 
protein on the surface of liver cells, to which the 1251_ 
CNTFY/sCNTFRa complex might bind. 
A side effect of CNTF after systemic application is 
the increase of haptoglobin gene expression in the liver 
(see Fig 8). Haptoglobin is an acute-phase protein [49}, 
whose gene expression is increased by CNTF in a hu-
man hepatoma cell line [31}. Stimulation of acute-
phase responses by recombinant human cytokines 
were also observed in vitro with primary hepatocytes 
and hepatoma cell lines for IL-6 [SO}, LIF [51}, and 
oncostatin M [52}, and in vivo for IL-6 [53,54]. There-
fore, one might assume that there are similar signaling 
pathways for these effects in hepatic cells. Indeed, the 
receptors of these cytokines are members of a hemato-
poietic cytokine receptor family [20, 55}, which use 
gp130 for signal transduction [43, 45, 56, 57}. Re-
cently, gp130 was also described as being involved in 
CNTF signal transduction in neuronal cells [43, 44}, 
as well as in an erythroleukemia cell line [43]. Our 
data concerning the cross-linking of 1251_CNTFY to 
membrane proteins of liver cells in situ (see Fig 7) 
suggest that gp130 and LIFR~ are involved in the ini-
tial CNTF signal transduction for the induction of 
acute-phase response in hepatocytes. Further experi-
ments are required to determine whether CNTF and 
LIF, which are believed to use the same initial signal 
transduction pathways (for reviews, see [21, 22}), in-
duce identical patterns of acute-phase proteins in 
liver. 
Taken together, our results indicate that systemic 
injection of CNTF might not lead to optimal availabil-
ity to motoneurons, the target cells for the clinical use 
of CNTF in motoneuron disease. Most i.v. injected 
CNTF is taken up (see Fig 3a) and degraded (Fig 4) 
by the liver. Not more than one trophic unit of 1251_ 
CNTFY per gram of tissue could be detected in the 
spinal cord 12 hours after i.v. injection of 0.5 f.Lg of 
12SI_CNTFY. Even under optimal diffusion conditions 
such as in cell culture, one trophic unit of CNTF would 
elicit only half-maximal response on neuronal survival. 
As CNTF is a protein of 200 amino acids, low diffusion 
within the extracellular space is expected to prevent 
the majority of CNTF from binding to its specific neu-
ronal receptors. Correspondingly, previous experi-
ments have shown that about 500 trophic units per 
milliliter of blood are necessary to improve motor 
function in pmn mice [8, 38}, an animal model of 
human motoneuron disease. 
Even if positive results with systematically adminis-
tered CNTF were obtained in ALS patients, our results 
indicate that optimization of CNTF delivery will be 
necessary to obtain maximal therapeutic benefit. One 
way to improve the bioavailability of compounds to 
the central nervous system (CNS) and nerve roots is 
intrathecal injection [58, 59], Alternatively, it might 
be necessary to use gene therapeutic approaches [60, 
61} to provide increased concentrations of CNTF 
within the CNS at its sites of action, i.e., motoneurons 
in the spinal cord and regions within the CNS con-
taining upper motoneurons. 
In addition, side effects of systemically administered 
CNTF on hepatocytes might further limit this thera-
peutical approach. From our study, we would predict 
the induction of acute-phase proteins as a side effect 
of CNTF in patients treated with pharmacological 
doses of this factor. However, quantitative toxicologi-
cal data relevant to the use of CNTF in patients can 
only be obtained from clinical trials. 
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